KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC)

Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers

(2013) V. W. Y. Lui et al.   Cancer Discovery

EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?

(2012) A Paliga et al.   BRITISH JOURNAL OF CANCER

PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy

(2012) John B. McIntyre et al.   GYNECOLOGIC ONCOLOGY

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study

(2012) Paola Ulivi et al.   Journal of Translational Medicine

Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell carcinomas

(2010) Nancy Van Damme et al.   BMC CANCER

The prognostic significance of tumor human papillomavirus status for patients with anal squamous cell carcinoma treated with combined chemoradiotherapy

(2010) Ho-Young Yhim et al.   INTERNATIONAL JOURNAL OF CANCER

Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma

(2010) Karl C. Bruckman et al.   ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS

K-ras status in squamous cell anal carcinoma (SCC): it’s time for target-oriented treatment?

(2009) Maria Giulia Zampino et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Cetuximab-Based Treatment of Metastatic Anal Cancer: Correlation of Response with KRAS Mutational Status

(2009) Nadine Lukan et al.   ONCOLOGY

Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer

(2009) Andrea Sartore-Bianchi et al.   PLoS One